These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 2966029)
21. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure. Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099 [TBL] [Abstract][Full Text] [Related]
22. Association between exogenous atrial natriuretic peptide and hemodynamics in dogs with congestive heart failure produced by experimental mitral regurgitation. Asano K; Masuda K; Okumura M; Kadosawa T; Fujinaga T J Vet Med Sci; 2001 Mar; 63(3):243-50. PubMed ID: 11307923 [TBL] [Abstract][Full Text] [Related]
23. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Kukkonen P; Vuolteenaho O; Ruskoaho H Endocrinology; 1992 Feb; 130(2):755-65. PubMed ID: 1531129 [TBL] [Abstract][Full Text] [Related]
24. Atrial natriuretic peptide (ANP) inhibits its own secretion via ANP(A) receptors: altered effect in experimental hypertension. Leskinen H; Vuolteenaho O; Toth M; Ruskoaho H Endocrinology; 1997 May; 138(5):1893-902. PubMed ID: 9112384 [TBL] [Abstract][Full Text] [Related]
25. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Yoshimura M; Yasue H; Okumura K; Ogawa H; Jougasaki M; Mukoyama M; Nakao K; Imura H Circulation; 1993 Feb; 87(2):464-9. PubMed ID: 8425293 [TBL] [Abstract][Full Text] [Related]
26. [Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3', 5'-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure]. Kobusiak-Prokopowicz M; Swidnicka-Szuszkowska B; Mysiak A Pol Arch Med Wewn; 2001 Jun; 105(6):475-82. PubMed ID: 11865578 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Lisy O; Lainchbury JG; Leskinen H; Burnett JC Hypertension; 2001 Apr; 37(4):1089-94. PubMed ID: 11304508 [TBL] [Abstract][Full Text] [Related]
33. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. van den Berg MP; Tjeerdsma G; Jan de Kam P; Boomsma F; Crijns HJ; van Veldhuisen DJ Eur J Heart Fail; 2002 Jun; 4(3):255-62. PubMed ID: 12034149 [TBL] [Abstract][Full Text] [Related]
34. Atrial natriuretic peptide in congestive heart failure. Fyhrquist F; Tikkanen I Am J Cardiol; 1988 Jul; 62(2):20A-24A. PubMed ID: 2968757 [TBL] [Abstract][Full Text] [Related]
35. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Tsutamoto T; Wada A; Maeda K; Hisanaga T; Maeda Y; Fukai D; Ohnishi M; Sugimoto Y; Kinoshita M Circulation; 1997 Jul; 96(2):509-16. PubMed ID: 9244219 [TBL] [Abstract][Full Text] [Related]
36. Augmented response in plasma atrial natriuretic peptide to dynamic exercise in patients with congestive heart failure. Kato M; Kinugawa T; Omodani H; Osaki S; Ogino K; Hisatome I; Miyakoda H; Fujimoto Y Jpn Circ J; 1996 Dec; 60(12):909-16. PubMed ID: 8996680 [TBL] [Abstract][Full Text] [Related]
37. Role of nitric oxide on cardiac hormone secretion: effect of NG-nitro-L-arginine methyl ester on atrial natriuretic peptide and brain natriuretic peptide release. Leskinen H; Vuolteenaho O; Leppäluoto J; Ruskoaho H Endocrinology; 1995 Mar; 136(3):1241-9. PubMed ID: 7867578 [TBL] [Abstract][Full Text] [Related]
38. Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Mizuno O; Onishi K; Dohi K; Motoyasu M; Okinaka T; Ito M; Isaka N; Nakano T Am J Cardiol; 2001 Oct; 88(8):863-6. PubMed ID: 11676948 [TBL] [Abstract][Full Text] [Related]
39. Preload-dependent hemodynamic effects of milrinone in moderate heart failure. Remme WJ; van Hoogenhuyze DC; Kruijssen HA; Pieper PG; Bruggeling WA Cardiology; 1992; 80(2):132-42. PubMed ID: 1611632 [TBL] [Abstract][Full Text] [Related]
40. Differences in blood pressure regulation of congestive heart failure, before and after treatment, correlate with changes in the circulating pattern of atrial natriuretic peptide. Portaluppi F; Montanari L; Ferlini M; Vergnani L; Bagni B; Degli Uberti EC Eur Heart J; 1992 Jul; 13(7):990-6. PubMed ID: 1386572 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]